Illustrations and 2D images
Maze Therapeutics (MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100 million in an initial public offering.
While the company did not reveal the terms in its SEC filingindicated in the table of deposit fees that
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1321450974/image_1321450974.jpg?io=getty-c-w750
Source link